The biological mystery of how many mammals transitioned from being nocturnal to active in the daytime following the extinction of the dinosaurs has been cracked by researchers in Cambridge. The study, ...
Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.
Differences in cellular pathway activity flip the switch from nocturnality to diurnality and explain a major evolutionary change humans have ...
Detailed price information for Palvella Therapeutics Inc (PVLA-Q) from The Globe and Mail including charting and trades.
BEYONDmLM.comcampaign designed to educate, engage, and empower patients, caregivers, and healthcare professionalsCampaign developed and launched ...
Premature ovarian insufficiency (POI) is a clinically significant cause of infertility that affects between 1 to 3% of women of childbearing age ...
As previously presented, gedatolisib + palbociclib + fulvestrant ('gedatolisib triplet”) and gedatolisib + fulvestrant ('gedatolisib doublet”) reduced the risk of disease progression or death versus ...
Premature ovarian insufficiency (POI) affects 1–3% of women and has limited treatment options. Researchers report that ...
The ovaries age faster than other organs, decreasing fertility over time. This article explores drivers of ovarian aging and ...
New corporate identity reflects the Company’s mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy ...
Researchers identified finerenone as a potential treatment for POI. Preclinical findings show the drug stimulates follicle ...
Filana Therapeutics, Inc. (formerly Cassava Sciences, Inc.) (NASDAQ: FLNA, “Filana Therapeutics”, the “Company”), a biotechnology company focused on developing novel medicines to modulate the filamin ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results